The kidney transplantation therapeutics market – Competitive Analysis, Recovery & Impact of COVID-19, Five Force Analysis” report has been added to Technavio’s offering. The kidney transplantation therapeutics market is estimated to grow by USD 643.15 million during 2024-2028, growing at a CAGR of 4.49%. The rising prevalence of CKD and renal impairments drives growth. The global burden of chronic kidney disease (CKD) is on the rise due to a growing number of cases of non-communicable diseases and their associated risk factors. Approximately 8.5%-9.5% of the adult population worldwide is affected by CKD. Major contributors to CKD include diabetes, hypertension, vascular disease, and glomerulonephritis. In many underdeveloped and developing nations, CKD is primarily attributed to glomerulonephritis and interstitial nephritis, driven by the high prevalence of infections.
For Comprehensive details on the size of historic period (2018 to 2022) and forecast period (2024-2028) – View the Free Sample report
The kidney transplantation therapeutics market is fragmented; the companies are competing with competitors and are trying to get greater share. The market is growing, and chances of new entrants cannot be overlooked. The major companies have well-established economies of scale and market presence and generally rely on positioning, technological advances, and the price of the products –The report provides a full list of key companies, their strategies, and the latest developments. Buy Now
- Increasing strategic alliances is an emerging trend in the market.
- The demand-supply imbalance for kidney transplantation is a major challenge hindering the growth.
Technavio has identified key trends, drivers, and challenges in the market, which will help clients improve their strategies to stay ahead of their competitors. – View the Free Sample Report
The kidney transplantation therapeutics report includes information on the product launches, sustainability, and prospects of leading companies including AbbVie Inc., Asahi Kasei Corp., Astellas Pharma Inc., B.Braun SE, Bristol Myers Squibb Co., Dr Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Fresenius Medical Care AG and Co. KGaA, GlaxoSmithKline Plc, Hansa Biopharma AB, Novartis AG, Organ Recovery Systems Inc., Pfizer Inc., Sanofi SA, Strides Pharma Science Ltd., TFF Pharmaceuticals Inc., TolerogenixX GmbH, TransMedics Inc., and Transonic Systems Inc..
Gain instant access to 17,000+ research reports.
Technavio’s SUBSCRIPTION platform
The report includes competitive analysis, a proprietary tool to analyze and evaluate the position of companies based on their industry position score and performance score. The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share, among others.
The growth by the selective cytokine inhibitors segment is significant during the forecast period. This category pertains to the utilization of medications that impede the production and activity of cytokines. Cytokines are signaling molecules within cells that facilitate the transmission of immune response signals between cells and promote the mobilization of immune cells toward foreign substances.
Kidney Transplantation Therapeutics; Applications
Kidney transplantation is a critical treatment for end-stage renal disease (ESRD), involving the surgical transfer of a donor kidney to a recipient. Immunosuppressive drugs like tacrolimus, mycophenolate mofetil, and sirolimus are crucial in preventing graft rejection. HLA matching ensures compatibility between donor and recipient, enhancing graft survival. Post-transplant care and monitoring are vital to manage complications like graft dysfunction and antibody-mediated rejection. This process depends on organ donation and procurement and plays a crucial role in nephrology, benefiting patients with chronic kidney disease (CKD) and kidney failure.
Related Reports
The renal anemia therapeutics market size is estimated to grow by USD 2.08 billion, at a CAGR of 7.59% between 2023 and 2028.
The equine supplement products market size is estimated to grow by USD 20,352.14 at a CAGR of 4.19% between 2023 and 2028.
1 Executive Summary
2 Landscape
3 Sizing
4 Historic Size
5 Five Forces Analysis
6 Segmentation by Product
7 Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Company Landscape
12 Company Analysis
13 Appendix
About US
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging trends and provide actionable insights to help businesses identify opportunities and develop effective strategies to optimize their positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable insights to identify opportunities in existing and potential markets and assess their competitive positions within changing scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio